Concepedia

Igor Odintsov

IO

Statistics

Publications

14

Citations

439

H-Index

13

Active since

2019

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Brigham and Women's Hospital

University of British Columbia

Harvard University

Oregon Health & Science University

Igor Odintsov is an author at Memorial Sloan Kettering Cancer Center specializing in molecular oncology, oncology, and medicine.

Publications per year

2019–2025

14

Publications

14

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Romel Somwar, Nicolle E. Hofmann, Bryan D. Smith et al. · Communications Biology · 2020 · 62 citations · Full text

Medicine, Oncology, Pharmacology +14

Acquired <i>MET</i> Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in <i>EGFR</i> -Mutated Lung Cancer

Ken Suzawa, Michael Offin, Adam J. Schoenfeld et al. · JCO Precision Oncology · 2019 · 54 citations · Full text

Medicine, Oncology, Pharmacology +17

The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic <i>NRG1</i> Fusions

Igor Odintsov, Allan J.W. Lui, Whitney J. Sisso et al. · Clinical Cancer Research · 2021 · 50 citations · Full text

Medicine, Cancer Biology, Oncology +16

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Isao Miyazaki, Igor Odintsov, Keiji Ishida et al. · Nature Cancer · 2023 · 37 citations · Full text

Medicine, Oncology, Pharmacology +13

Prognostic and predictive biomarkers in non-small cell lung carcinoma

Igor Odintsov, Lynette M. Sholl · Pathology · 2023 · 35 citations

Medicine, Cancer Biology, Oncology +14

1–5 of 14